Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories reported consolidated revenue from operations of ₹129,645.2 Million for FY25, up about 2.3% from ₹126,675.8 Million in FY24. Net profit for the year rose to ₹22,153.8 Million from ₹18,114.6 Million, a growth of roughly 22%, with EPS of ₹181.11 versus ₹150.19. Q4FY25 revenue stood at ₹31,437.5 Million (vs ₹29,358.2 Million in Q4FY24) and Q4 PAT at ₹3,223.9 Million. The Board has recommended a final dividend of ₹8 per share, taking total FY25 dividend to ₹45 per share (including ₹37 interim). Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated results. The Board also appointed two new Independent Directors and M/s. Manish Ghia & Associates as Secretarial Auditors for a 5-year term.
Clean audit opinion, healthy profit growth of about 22%, and a strong total dividend of ₹45/share are positive for shareholders, though top-line revenue growth was modest at around 2%. The auditor change from the predecessor firm to Deloitte is noteworthy and reflects governance continuity. Overall, the results support steady shareholder returns with margin expansion.